^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Glycolysis inhibitor

2d
Nebulized AER101 in Pre-op NSCLC (clinicaltrials.gov)
P1, N=5, Not yet recruiting, University of Oklahoma
New P1 trial
2d
Sulconazole Suppresses Colorectal Cancer Immune Evasion by Inhibiting Glycolysis to Upregulate OVOL2 PARylation and Induce PANoptosis. (PubMed, FASEB J)
Sulconazole blocks glycolysis-driven PD-L1 expression and restores OVOL2 function, inducing PANoptosis and reversing immune evasion. Repurposing sulconazole offers a promising strategy for glycolytic, immunosuppressive CRC.
Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
PD-L1 expression
8d
Investigation of the relationship between autophagy and Warburg effect in osteosarcoma cells: An in vitro study. (PubMed, Cancer Treat Res Commun)
This study reveals crosstalk between autophagy and the Warburg effect in Saos-2 cells, where glycolytic stress triggers protective autophagy and its inhibition alters metabolism, promoting apoptosis.
Preclinical • Journal
|
ATG3 (Autophagy Related 3) • BECN1 (Beclin 1) • PFKP (Phosphofructokinase, Platelet)
|
chloroquine phosphate
10d
Lactylation-augmented DCBLD1-mediated PDIA3 stabilization reprograms glycolysis metabolism in oesophageal cancer. (PubMed, J Cancer Res Clin Oncol)
It was established that DCBLD1 lactylation bound to PDIA3, contributing to oesophageal cancer malignancy and glycolysis.
Journal
|
LDHA (Lactate dehydrogenase A) • PDIA3 (Protein Disulfide Isomerase Family A Member 3)
14d
Development of Type II Glucose Transporter Inhibitors: Phloretin as a GLUT-2 Screening Template from In Silico Modeling to In Vitro Assessment. (PubMed, Biomedicines)
Glucose uptake at sub-cytotoxic levels was quantified using the fluorescent analog 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose... These results demonstrate that phloretin selectively inhibits glucose uptake in liver cancer cells, likely through its high-affinity interaction with GLUT-2. Collectively, these findings highlight phloretin's potential as a metabolic therapeutic agent and support GLUT-2 as a viable target for HCC intervention.
Preclinical • Journal
|
SLC2A1 (Solute Carrier Family 2 Member 1)
24d
Lactylation-induced TRIM47 exacerbates cell viability, cell cycle progression, and glycolysis in thyroid cancer by inducing ubiquitin-mediated degradation of FBP1. (PubMed, Pathol Res Pract)
The oncogenic phenotypes driven by TRIM47 overexpression on cellular viability and the cell cycle were counteracted by either administration of the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) or by forced expression of FBP1...As the core effector molecule in the lactic acid-H3K18la epigenetic circuit, TRIM47 drives tumorigenesis by inducing ubiquitin-mediated degradation of FBP1. Targeting of this signaling axis holds significant promise for the development of new thyroid cancer therapies.
Journal
|
FBP1 (Fructose-Bisphosphatase 1) • TRIM47 (Tripartite Motif Containing 47)
24d
Lactylation of β-catenin promotes non-small cell lung cancer by inhibiting ferroptosis through TCF4-mediated GPX4 transcription. (PubMed, J Transl Med)
Cell models were established in BEAS-2B and NSCLC cell lines, with lactylation regulated by lactate (LA) and 2-deoxyglucose (2-DG)...Mechanistically, β-catenin K193 lactylation reduced LPO and increased GSH to suppress ferroptosis: lactylated β-catenin translocated to the nucleus, formed a complex with TCF4, and upregulated GPX4 transcription by binding its promoter. GPX4 overexpression reversed ferroptosis induced by β-catenin K193 lactylation inhibition, while blocking β-catenin/TCF4 interaction downregulated GPX4 and enhanced ferroptosis.
Journal
|
GPX4 (Glutathione Peroxidase 4) • TCF4 (Transcription Factor 4)
1m
Efficacy of LNP@2DG-DON liposomal nanoparticles in tumor inhibition and immune activation. (PubMed, J Transl Med)
The dual-targeting LNP@2DG-DON nanoparticle synergistically combines metabolic and immune modulation, demonstrating superior antitumor effects compared to single-agent therapies. This approach represents a promising strategy for pancreatic cancer treatment, warranting further clinical investigation.
Journal
|
CD8 (cluster of differentiation 8)
1m
PFKP Drives Immune Checkpoint Co-Expression and Metabolic Pathway Activation in Liver Cancer: TCGA-Based and Experimental Validation. (PubMed, Clin Transl Gastroenterol)
PFKP is a critical link between glycolysis and immune suppression in HCC. It promotes immune checkpoint expression and mTOR activation, suggesting a role in immune evasion. PFKP represents a dual biomarker for prognosis and immunotherapy response, and a promising target for combined metabolic and immune-based therapies.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PFKP (Phosphofructokinase, Platelet)
|
PD-L1 expression
2ms
Disrupting the TGF-β-regulated epithelial-mesenchymal transition, apoptotic and autophagic phenotypes of 3D glioblastoma spheroids via glycolytic inhibition. (PubMed, Explor Target Antitumor Ther)
2-Deoxy-D-glucose (2DG), a glycolytic inhibitor, depleted ATP dose-dependently (30-300 μM) and prevented those increases both at the protein and transcriptional levels. This was also observed in 3D spheroids upon TGF-β transient siRNA-mediated silencing or when TGF-βR1 kinase activity was inhibited by galunisertib...3D spheroids require ATP and a TGF-β/TGF-βR1 autocrine signaling axis to recapitulate the apoptosis/autophagy phenotypes. Combining glycolysis inhibition with TGF-β signaling inhibition could offer a promising therapeutic strategy for this rare and lethal brain cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • FASLG (Fas ligand) • TGFB1 (Transforming Growth Factor Beta 1) • CASP7 (Caspase 7) • PIK3C3 (Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3) • ATG16L1 (Autophagy Related 16 Like 1) • ATG7 (Autophagy Related 7)
|
galunisertib (LY2157299)
2ms
Multi-omics analysis of gut microbiota and gene expression reveals that TBK1 promotes colorectal tumorigenesis by activating glycolysis. (PubMed, Acta Microbiol Immunol Hung)
Functionally, TBK1 promoted cell proliferation and colony formation while inhibiting apoptosis, which were attenuated by the glycolytic inhibitor 2-deoxy-D-glucose. These findings establish TBK1 as a critical mediator linking GM dysbiosis to metabolic reprogramming in CRC, suggesting that targeting the TBK1-glycolysis axis may represent a promising therapeutic strategy for delaying CRC progression.
Journal
|
HK2 (Hexokinase 2) • TBK1 (TANK Binding Kinase 1)